People with type 2 diabetes using our GlucoMON wireless glucose meter for mobile diagnostics, the GlucoDYNAMIX rules engine and connectivity with their social networks enjoyed significant reductions in their A1c levels. This is just another of many r…

My session was pretty well attended and included talks from Satish Garg, Lois Janovic, yours truly, Steve Edelman and Mayer Davidson focused on extender technologies and programs that reach beyond traditional practice-based care. I have blogged a little so far at ChallengeDiabetes.com and will continue to add as I digest the conference.

I announced some very exciting trial results for our type 2 patients. Type 1 results are forthcoming. Essentially, the combination of consumer-ish technology with diabetes devices, rules engine technology and social networks leads to improved outcomes and practice efficiencies.

Even Dr. Garg, one of the leading researchers behind clinical evaluation of CGMS understood the value of integrating the real-time sensor into a real-time system like the one we use in our programs.

My prediction for the next year is a heightened awareness around accuracy at every point in diabetes care. Fine tuning what we have now is going to be necessary before we move to automated dosing, etc… Let’s get the data right then we can take the next big step.

By the way, Sarah, I want to mention that I agree with what you said above: I don’t want the medical community to give us more depressing study results if we aren’t being offered any better ways to manage our disease. We’re all striving for good A1c’s and doing the best we can with the tools we have. I have no doubt that diabetes affects every single aspect of health — someone will come out with a study claiming diabetics are more likely to get the Ebola virus, or fall off buildings during hypoglycemic episodes, etc. I’d rather that these studies give us more info regarding prevention rather than reminding us we’re doomed.

Not enough research is being done on it. It’s believed that c-peptide functions in the muscle layer of arteries and according to Diabetes 55:3581-3587, 2006, an article states that c-peptide reverses neuropathy in type 1 diabetes (in rats).

I would be curious to know if any drug companies have c-peptide in their drug pipeline.

Finding a way to safely deliver it (or even include it with insulin) would guarantee a large amount of income for the company that comes to market with the first patent.

As far as I know, there is currently no way to replace C-peptide. If Lilly or Novo Nordisk added C-peptide to their vials of insulin they could probably make another couple billion dollars, so there’s probably an incentive to develop it. I think we type 1’s would be better off for it.

If anyone else knows about C-peptide research as it pertains to diabetics, I’d love to hear more.

Lately, I’ve seen so many people ask about Type 1 diabetes and “hearing loss” that I knew there must be a link.

All this in addition to factor “x” that has been linked to “diabetic hearing loss”, which most likely is high blood sugar. Perhaps diabetics also have a higher incidence of ear infections?

Either way, it’s common sense that high blood sugars can damage to the brain, nerves, and blood vessels in every part of the body. New evidence also suggests that LOW blood sugar may cause nerve damage as well.

Are we going to cure this disease, or just waste more time and money looking for ways to “manage” and study it? When it comes to Type 1 diabetes, studies like this are an insult.

Oh well, perhaps one day these stupid studies (how is knowing this useful if we can’t do anything more than we are already doing?) will fall on “deaf ears”…hehe